Glaukos (NYSE:GKOS) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a report issued on Wednesday.
GKOS has been the topic of several other reports. BMO Capital Markets restated a “buy” rating on shares of Glaukos in a research note on Monday, December 11th. William Blair restated an “outperform” rating on shares of Glaukos in a research note on Friday, March 23rd. Cantor Fitzgerald set a $48.00 target price on Glaukos and gave the company a “buy” rating in a research note on Wednesday, January 10th. Zacks Investment Research lowered Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 13th. Finally, Canaccord Genuity lowered their target price on Glaukos from $48.00 to $43.00 and set a “buy” rating on the stock in a research note on Thursday, March 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. Glaukos has a consensus rating of “Buy” and an average target price of $41.25.
Glaukos stock traded down $0.14 during mid-day trading on Wednesday, reaching $31.81. 22,157 shares of the company’s stock were exchanged, compared to its average volume of 556,990. The firm has a market capitalization of $1,115.88, a P/E ratio of 214.13 and a beta of 1.05. Glaukos has a one year low of $23.08 and a one year high of $51.51.
In other news, Director Orbimed Advisors Llc sold 836,500 shares of Glaukos stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $32.02, for a total value of $26,784,730.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jonathan Silverstein sold 464,583 shares of Glaukos stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $32.29, for a total value of $15,001,385.07. The disclosure for this sale can be found here. 16.40% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. C WorldWide Group Holding A S grew its position in shares of Glaukos by 0.7% in the fourth quarter. C WorldWide Group Holding A S now owns 293,360 shares of the medical instruments supplier’s stock valued at $7,525,000 after purchasing an additional 1,935 shares in the last quarter. Geode Capital Management LLC grew its position in Glaukos by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 275,937 shares of the medical instruments supplier’s stock worth $7,077,000 after buying an additional 2,268 shares in the last quarter. First Republic Investment Management Inc. grew its position in Glaukos by 47.1% during the third quarter. First Republic Investment Management Inc. now owns 8,300 shares of the medical instruments supplier’s stock worth $274,000 after buying an additional 2,659 shares in the last quarter. Valeo Financial Advisors LLC purchased a new position in Glaukos during the third quarter worth about $111,000. Finally, Granite Investment Partners LLC grew its position in Glaukos by 7.7% during the fourth quarter. Granite Investment Partners LLC now owns 48,375 shares of the medical instruments supplier’s stock worth $1,241,000 after buying an additional 3,464 shares in the last quarter.
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.